Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026

Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025

Same author

Epithelial cell, keratocyte, and endothelial cell apoptosis in Fuchs dystrophy and in pseudophakic bullous keratopathy.

European journal of ophthalmology·2017

Same author

Metabolism of selegiline [(-)-deprenyl)].

Current medicinal chemistry·2013

Same author

Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.

Cell death & disease·2013

Same author

Measures to prevent transfusion-related acute lung injury (TRALI).

Vox sanguinis·2012

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

R-deprenyl: pharmacological spectrum of its activity.

K Magyar¹, B Szende, V Jenei

¹Department of Pharmacodynamics, Semmelweis University, H-1445, Budapest, POB 370, Hungary. kalman.magyar@net.sote.hu

Neurochemical Research

|August 21, 2010

Summary

Selegiline (R-deprenyl) is a selective MAO-B inhibitor used for Parkinson's disease. It offers neuroprotection by reducing oxidative stress and has beneficial effects beyond MAO-B inhibition.

More Related Videos

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Related Experiment Videos

Last Updated: Jun 10, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Area of Science:

Neuroscience
Pharmacology
Biochemistry

Background:

Selegiline (R-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B).
It has established efficacy in treating Parkinson's disease due to dopamine-potentiating and neuroprotective effects.
Oxidative stress, implicated in neurodegeneration, is modulated by MAO-B activity.

Purpose of the Study:

To elucidate the multifaceted neuroprotective mechanisms of selegiline.
To investigate the role of MAO-B inhibition and non-MAO-B-related effects in selegiline's neuroprotection.
To explore the contribution of selegiline metabolites, such as deprenyl-N-oxide, to its pharmacological profile.

Main Methods:

Review of existing literature on selegiline's biochemical and pharmacological actions.
Analysis of studies investigating selegiline's effects on oxidative stress markers and antioxidant enzyme expression.
Examination of research on selegiline's efficacy against neurotoxins (e.g., MPTP, DSP-4).

Main Results:

Selegiline inhibits MAO-B, reducing hydrogen peroxide formation and oxidative stress.
Chronic selegiline treatment increases antioxidant enzyme expression (superoxide dismutases, catalase).
Neuroprotective and neuronal rescue effects are observed at concentrations below those required for MAO-B inhibition, suggesting alternative mechanisms.

Conclusions:

Selegiline exhibits significant neuroprotective properties in Parkinson's disease models.
Its therapeutic benefits stem from both MAO-B inhibition and other, non-enzymatic mechanisms.
Metabolites of selegiline, including deprenyl-N-oxide, may contribute to its overall efficacy and influence cellular processes like adhesion and proliferation.